/CRGX
CRGX Stock - CARGO Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$4.47+0.00%
+$0.00 (+0.00%) • Aug 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+56.6%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.43 – $4.51
TARGET (TP)$7.00
STOP LOSS$4.11
RISK/REWARD1:7.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.29
52W High$25.45
52W Low$3.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | $-7,074,000 | $-3,692,000 | $-1,444,000 | $-147,000 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-187,370,000 | $-96,710,000 | $-34,771,000 | $-5,977,000 |
| Net Income | $-167,502,000 | $-98,147,000 | $-40,951,000 | $-5,850,000 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-3.72 | $-2.38 | $-2.13 | $-0.30 |
Company Overview
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
55%
Hold / Neutral
5
45%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish5 Neutral/Bearish
Price Targets
$22
Average Target
↑ 389.7% Upside
Now
$3
Low
$22
Average
$37
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 30th 2025 | Chardan Capital Markets | Downgrade | Neutral | - |
| January 30th 2025 | Jefferies | Downgrade | Hold | $3← $32 |
| January 30th 2025 | Piper Sandler | Downgrade | Neutral | $4← $34 |
| January 30th 2025 | William Blair | Downgrade | Market Perform | - |
| January 30th 2025 | JP Morgan | Downgrade | Underweight | - |
| January 30th 2025 | Truist | Downgrade | Hold | $7← $32 |
| January 30th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| November 26th 2024 | William Blair | Initiation | Outperform | - |
| July 22nd 2024 | H.C. Wainwright | Initiation | Buy | $33 |
| July 8th 2024 | Chardan Capital Markets | Initiation | Buy | $28 |
| June 27th 2024 | Piper Sandler | Initiation | Overweight | $37 |
| December 5th 2023 | Truist | Initiation | Buy | $34 |
| December 5th 2023 | Jefferies | Initiation | Buy | $28 |
| December 5th 2023 | JP Morgan | Initiation | Overweight | $23 |
| December 5th 2023 | TD Cowen | Initiation | Outperform | - |
Earnings History & Surprises
CRGXBeat Rate
63%
Last 8 quarters
Avg Surprise
-192.2%
EPS vs Estimate
Beats / Misses
5/2
1 met exactly
Latest EPS
$-0.27
Q3 2025
EPS Surprise History
Q4 23
-1604.0%
$-47.37vs$-2.78
Q1 24
+8.0%
$-1.49vs$-1.62
Q2 24
+17.1%
$-0.87vs$-1.05
Q3 24
+3.8%
$-1.02vs$-1.06
Q4 24
+22.8%
$-0.88vs$-1.14
Q1 25
0.0%
$-0.95vs$-0.95
Q2 25
-14.3%
$-0.80vs$-0.70
Q3 25
+28.9%
$-0.27vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.37 | — | — | — |
Q3 2025 | Aug 6, 2025 | $-0.38 | $-0.27 | +28.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.70 | $-0.80 | -14.3% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-0.95 | $-0.95 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-1.14 | $-0.88 | +22.8% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-1.06 | $-1.02 | +3.8% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.05 | $-0.87 | +17.1% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-1.62 | $-1.49 | +8.0% | ✓ BEAT |
Q4 2023 | Dec 13, 2023 | $-2.78 | $-47.37 | -1604.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | — | $-0.46 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.33 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.47 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.63 | — | — |
Frequently Asked Questions about CRGX
What is CRGX's current stock price?
CARGO Therapeutics, Inc. Common Stock (CRGX) is currently trading at $4.47 per share. The stock has moved +0.00% today.
What is the analyst price target for CRGX?
The average analyst price target for CRGX is $7.00, based on 1 analyst.
What sector is CARGO Therapeutics, Inc. Common Stock in?
CARGO Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRGX's market cap?
CARGO Therapeutics, Inc. Common Stock has a market capitalization of $0.22 billion, making it a small-cap company.
Does CRGX pay dividends?
No, CARGO Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCBLI
Cytocom, Inc.
$3.17
Mkt Cap: $0.2B
INXB
Inhibrx Biosciences, Inc.
$15.86
Mkt Cap: $0.2B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
LSB
LakeShore Biopharma Co., Ltd
$0.63
Mkt Cap: $0.0B
MACK
Merrimack Pharmaceuticals, Inc.
$15.14
Mkt Cap: $0.2B
SLRN
Acelyrin, Inc.
$2.27
Mkt Cap: $0.2B
SPPI
Spectrum Pharmaceuticals, Inc.
$1.02
Mkt Cap: $0.2B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VACC
Vaccitech plc
$5.00
Mkt Cap: $0.2B
ZVRA
Zevra Therapeutics, Inc.
$8.31
Mkt Cap: $0.5B
Explore stocks similar to CRGX for comparison